Intensity Therapeutics INTS
NASDAQ INTS
$3.19 +0.05 (+1.51%)
As of: Oct 22, 2026 · 1:44 PM EDT

Intensity Therapeutics (INTS) Net Debt Issuances and Repayments (2023)

Updated

Analysis

Intensity Therapeutics (INTS) Net Debt Issuances and Repayments (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Debt Issuance (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 11.58 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -4.36 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -2.00 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -5.00 Mn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 2.17 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn -2.46 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -17.00 Mn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 64.00 Mn
10 Intensity Therapeutics 8.63 Mn -30.13 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -13,000.00
Jun 30, 2023 38,000.00
Mar 31, 2023 205,000.00
API Access

Intensity Therapeutics Net Debt Issuances and Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-debt-issuances-and-repayments&ticker=INTS&period=max&api_key=YOUR_API_KEY